The UK Supreme Court has now issued its judgement in the long
running Regeneron v Kymab transgenic mouse cases, finding
the Regeneron patents invalid for lack of sufficiency.
Regeneron Pharmaceuticals Inc sued Kymab Ltd for infringement of
their transgenic mouse patents (EP1360287 and EP2264163). The mice
covered by the Regeneron patents included a combination of mouse
and human DNA, meaning that they produced antibodies that can be
used in the treatment of human illnesses without causing
immunological sickness in a mouse. The Kymab mice (Kymice) have a
similar genetic structure to the Regeneron mice. Kymab's
defence against their alleged infringement was that the Regeneron
patents were invalid for lacking sufficiency.